Balanced news tone
News Sentiment
OPK sentiment intelligence
Opko Health Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.
Price is moving more forcefully than the current news tone suggests.
79/100 classification confidence.
directly relevant articles
high-authority source matches
-11.2% over one week, -4.9% over four weeks, trend active, and near fair-value range.
OPK5733212 Bond Profile — Key Metrics
Market Reaction
Price moving ahead of tone
Price is moving more forcefully than the current news tone suggests.
Sentiment Mix
Positive, neutral, negative
Relevance
Why the article matched
Sources
Coverage mix
Event Lens
What the news is about
Sentiment Trail
Score over time
News Tape
Relevant headlines
OPK5733212 Bond Profile — Key Metrics
This article provides key metrics for the OPK5733212 bond issued by OPKO Health, Inc. The bond has a 3.75% coupon rate, was issued on January 9, 2024, and matures on January 15, 2029, with a face value of $1,000. OPKO Health, Inc. is described as a biopharmaceutical and diagnosti
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 15 Jul 2026 02:11
- Source
- TradingView
Zacks Research Has Weak Estimate for OPKO Health Q2 Earnings
Zacks Research has reduced its Q2 2028 EPS estimate for OPKO Health (NASDAQ:OPK) to -$0.05 from -$0.04, reflecting a weaker outlook, though the full-year estimate remains at -$0.29 per share. This follows the company's recent quarterly results where EPS matched expectations at -$
- Tone
- Negative 31/100
- Event
- Earnings
- Published
- 13 Jul 2026 05:39
- Source
- MarketBeat
ETFs Investing in OPKO Health, Inc. Stocks
This article lists various ETFs that invest in OPKO Health, Inc. stocks. It provides a detailed table including each ETF's market value, weight of OPKO in its holdings, issuer, management style, expense ratio, AUM, price, and 3-year NAV total return. The ETFs cover different inve
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 10 Jul 2026 20:10
- Source
- TradingView
Qiagen N.V. highlights molecular diagnostics growth as investors eye global health demand
- Tone
- Positive 66/100
- Event
- Macro sensitivity
- Published
- 06 Jul 2026 06:41
- Source
- Ad Hoc News
OPKO Health (OPK) Piper Sandler 36th Annual Healthcare Conference Summary
OPKO Health presented at the Piper Sandler 36th Annual Healthcare Conference, highlighting the growth of its Ngenla human growth hormone, with Pfizer projecting $500 million to $1 billion in near-term sales. The company also discussed its ModeX platform for multispecific antibodi
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 05 Jul 2026 20:10
- Source
- Quartr
OPK - Opko Health Inc Options
This article provides a comprehensive overview of Opko Health Inc. (OPK) stock, including its latest closing price, key financial metrics, performance indicators, and ownership details. It details statistics such as market capitalization, income, sales, P/E ratio, EPS, insider an
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 03 Jul 2026 17:40
- Source
- Finviz
OPKO Health Inc focuses on diagnostics and pharmaceuticals as investors weigh long-term prospects
OPKO Health Inc is building its business around both diagnostic services and specialty pharmaceutical products. The company aims to diversify its revenue streams and capitalize on growth opportunities in the healthcare sector. Investors are closely monitoring OPKO's strategy for
- Tone
- Positive 64/100
- Event
- Earnings
- Published
- 03 Jul 2026 15:10
- Source
- Ad-hoc-news.de
Form 13D/A OPKO HEALTH For: 1 July By Investing.com
This article announces that OPKO Health has filed a Form 13D/A for July 1st. It also includes general market data, popular news, and various financial statistics. The content itself provides no further details beyond the filing announcement.
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 03 Jul 2026 07:10
- Source
- Investing.com UK
OPKO Health (OPK) Ownership Update Draws Attention, Is The 55% Undervalued View Convincing?
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 02 Jul 2026 07:00
- Source
- simplywall.st
Phillip Frost (NASDAQ: OPK) reports 34.1% beneficial stake in OPKO
Phillip Frost has reported a significant 34.1% beneficial stake in OPKO Health (NASDAQ: OPK), totaling 255,429,406 shares. This ownership includes holdings through Gamma Trust, Frost Nevada Investments Trust, a philanthropic foundation, stock options, and restricted stock units.
- Tone
- Neutral 50/100
- Event
- Deals and strategy
- Published
- 01 Jul 2026 19:39
- Source
- Stock Titan
Enterprise value to EBITDA forward of Opko Health, Inc. – NASDAQ:OPK
This article presents financial data for Opko Health, Inc. (NASDAQ: OPK), specifically focusing on its enterprise value to EBITDA forward metric. The content was sourced from TradingView and includes general company and market information, but the specific financial value for the
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 29 Jun 2026 06:10
- Source
- TradingView
OPKO Health, Inc. Actuals & Estimates (BMV:OPK)
This article provides an overview of OPKO Health, Inc. (BMV:OPK) stock, including current price, analyst forecasts, historical highs and lows, volatility, market capitalization, and financial reports. It also details recent earnings, revenue, net income, and confirms that the com
- Tone
- Negative 35/100
- Event
- Earnings
- Published
- 27 Jun 2026 07:09
- Source
- TradingView
Price to earnings forward of OPKO Health, Inc. – FWB:XCY
This article provides a financial metric, the "Price to earnings forward," for OPKO Health, Inc. (FWB:XCY) on the TradingView platform. It indicates that the company's financial data is available for review, though no specific values are presented in this snippet. The content pri
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 27 Jun 2026 03:10
- Source
- TradingView
Price to sales forward of Opko Health, Inc. – NASDAQ:OPK
This page from TradingView displays information related to the forward price-to-sales ratio for Opko Health, Inc. (NASDAQ: OPK). It indicates that the content is a financial data point for the company, accessible through the platform's market data and financial tools. The page it
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 27 Jun 2026 00:09
- Source
- TradingView
Price to book forward of OPKO Health, Inc. – FWB:XCY
The article focuses on the "Price to book forward" metric for OPKO Health, Inc. (FWB:XCY) listed on the Frankfurt Stock Exchange. It provides financial data context without presenting specific values in the clean content. The page also outlines various features and services offer
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 26 Jun 2026 19:09
- Source
- TradingView
OPKO Health, Inc. Actuals & Estimates (NASDAQ:OPK)
This article provides an overview of OPKO Health, Inc. (NASDAQ: OPK) stock, including its current price, market capitalization, historical highs and lows, and analyst forecasts. It also details the company's financial actuals and estimates for earnings and revenue, noting that OP
- Tone
- Positive 64/100
- Event
- Earnings
- Published
- 26 Jun 2026 11:09
- Source
- TradingView
XCY Forecast — Price Target — Prediction for 2027
This article provides a forecast and price target for OPKO Health, Inc. (XCY) stock based on analyst opinions. It includes details on the company's past performance, earnings, revenue, and other financial metrics. The article also addresses frequently asked questions about XCY, s
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 25 Jun 2026 20:40
- Source
- TradingView
OPKO Health, Inc. Actuals & Estimates (TASE:OPK)
This article provides an overview of OPKO Health, Inc. (TASE:OPK) stock, including its current price, performance, analyst forecasts, and financial data. It covers historical price movements, market capitalization, earnings reports, revenue, EBITDA, and employee count, alongside
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 25 Jun 2026 18:41
- Source
- TradingView
OPK Forecast — Price Target — Prediction for 2027
This article provides a detailed forecast and price target for Opko Health, Inc. (OPK) stock for 2027, based on analyst opinions. It includes current stock performance metrics, historical highs and lows, financial data like earnings and revenue forecasts, and other relevant compa
- Tone
- Positive 61/100
- Event
- Earnings
- Published
- 25 Jun 2026 17:41
- Source
- TradingView
OPKO Health (OPK) Stock Could Be 57% Undervalued As Margin Recovery Comes Into Focus
OPKO Health (OPK) is currently trading at $1.46, with analysts suggesting it could be 57% undervalued, pointing to a fair value of $3.40. This valuation is based on expected margin recovery after the sale of BioReference's oncology assets, aiming for profitability in its Diagnost
- Tone
- Positive 65/100
- Event
- Earnings
- Published
- 25 Jun 2026 09:40
- Source
- Sahm
OPKO HEALTH (OPK) director receives 80,000-share stock option grant
OPKO Health director Uppaluri Subbarao V received a grant of stock options for 80,000 shares as part of standard director compensation. These options have an exercise price of $1.42 per share, become exercisable on June 18, 2027, and expire on June 17, 2036. The grant involved ca
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 23 Jun 2026 13:39
- Source
- Stock Titan
Director at OPKO (NASDAQ: OPK) receives grant of 60,000 stock options
OPKO Health, Inc. director Richard C. Pfenniger Jr. was granted 60,000 stock options with an exercise price of $1.42 per share. These options become exercisable on June 18, 2027, and expire on June 17, 2036. This transaction was reported via an SEC Form 4 filing, indicating an aw
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 23 Jun 2026 01:40
- Source
- Stock Titan
Form 4 Opko Health For: 22 June By Investing.com
The article "Form 4 Opko Health For: 22 June" by Investing.com reports on a Form 4 filing for Opko Health (OPK) dated June 22, 2026. This brief piece, which appears to be a standard financial markets update, mentions the company's stock performance (+2.74%) and reiterates the For
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 23 Jun 2026 01:10
- Source
- Investing.com Nigeria
Opko Health (OPK) director Roger Medel receives 30,000 stock options grant
Opko Health (OPK) director Roger Medel has been granted 30,000 stock options, with an exercise price of $1.42 per share. These options will become exercisable on June 18, 2027, and have an expiration date of June 17, 2036. This transaction is considered a grant or award of deriva
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 22 Jun 2026 21:39
- Source
- Stock Titan
Opko Health (OPK) director awarded 30,000 stock options at $1.42 strike
OPKO Health director John A. Paganelli was granted 30,000 stock options at an exercise price of $1.42 per share as compensation. These options become exercisable on June 18, 2027, and will expire on June 17, 2036. Following this grant, Paganelli directly holds 30,000 options.
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 22 Jun 2026 21:39
- Source
- Stock Titan
OPKO Health (OPK) director receives 30,000-share stock option award at $1.42
OPKO Health director Prem A. Lachman was granted options for 30,000 shares of common stock at an exercise price of $1.42 per share on June 18, 2026. This award is compensation-related, not an open-market transaction, and brings his directly held option position to 30,000 shares w
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 22 Jun 2026 21:39
- Source
- Stock Titan
Opko Health Shareholders Back Board, Equity and Auditors
Opko Health shareholders re-elected all eleven nominees to the Board of Directors, approved the 2026 Equity Incentive Plan, and endorsed executive compensation at their Annual Meeting. They also ratified Ernst & Young LLP as the independent auditor. Despite weak financial perform
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 19 Jun 2026 20:39
- Source
- The Globe and Mail
Should OPKO’s New 15% Nicoya Stake and RAYALDEE Terms Require Action From OPKO Health (OPK) Investors?
- Tone
- Neutral 50/100
- Event
- Deals and strategy
- Published
- 11 Jun 2026 07:00
- Source
- simplywall.st
Assessing OPKO Health (OPK) Valuation After Expanded Nicoya RAYALDEE Partnership In Greater China
- Tone
- Neutral 50/100
- Event
- Deals and strategy
- Published
- 07 Jun 2026 07:00
- Source
- Market source
How Investors May Respond To OPKO Health (OPK) Boosting Its Nicoya Stake And RAYALDEE Milestones
- Tone
- Neutral 50/100
- Event
- Deals and strategy
- Published
- 06 Jun 2026 07:00
- Source
- Market source